AbstractIdiopathic membranous nephropathy is a common cause of nephrotic syndrome, and has been reported as a cause of idiopathic primary glomerulonephropathy in up to 90% of patients. However, the treatment options remain controversial. We report two cases of idiopathic membranous nephropathy that were treated with rituximab. A 54-year-old man and a 64-year old man were admitted for rituximab therapy. They had previously been treated with combinations of immunosuppressive agents including cyclophosphamide, cyclosporine, mycophenolate, and steroids. However, the patients' heavy proteinuria was not resolved. Both patients received rituximab therapy, 2 weeks apart. After several months of follow-up and a second round of rituximab treatment fo...
Background/Aims: First-line immunosuppression with the B-cell depleting antibody rituximab reduced p...
Rituximab effectively reduces proteinuria in patients with idiopathic membranous nephropathy (IMN), ...
INTRODUCTION: Patients with phospholipase A2 receptor (PLA2R)-associated membranous nephropathy and ...
AbstractIdiopathic membranous nephropathy is a common cause of nephrotic syndrome, and has been repo...
Idiopathic membranous nephropathy is a common cause of nephrotic syndrome whose pathogenesis may inv...
BACKGROUND: Membranous nephropathy is a common cause of the nephrotic syndrome. Treatment with stand...
Background: Rituximab representsavalid therapeutic option to induce remissioninpatients with primary...
The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for glomerul...
Primary membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. The disease m...
Immunosuppressive therapy is mandatory for primary membranous nephropathy with persistent nephrotic ...
We present a 59-year-old patient with type 2 diabetes mellitus and massive nephrotic syndrome (anasa...
The ideal treatment of patients with primary membranous nephropathy (MN) and persistent nephrotic sy...
Kimura disease (KD) is a chronic, inflammatory disorder with slowly developing subcutaneous tumor-li...
The development of well-tolerated and effective therapies that target the pathogenesis of membranous...
IntroductionThere is broad consensus that high-grade basal proteinuria and failure to achieve remiss...
Background/Aims: First-line immunosuppression with the B-cell depleting antibody rituximab reduced p...
Rituximab effectively reduces proteinuria in patients with idiopathic membranous nephropathy (IMN), ...
INTRODUCTION: Patients with phospholipase A2 receptor (PLA2R)-associated membranous nephropathy and ...
AbstractIdiopathic membranous nephropathy is a common cause of nephrotic syndrome, and has been repo...
Idiopathic membranous nephropathy is a common cause of nephrotic syndrome whose pathogenesis may inv...
BACKGROUND: Membranous nephropathy is a common cause of the nephrotic syndrome. Treatment with stand...
Background: Rituximab representsavalid therapeutic option to induce remissioninpatients with primary...
The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for glomerul...
Primary membranous nephropathy (MN) is a common cause of nephrotic syndrome in adults. The disease m...
Immunosuppressive therapy is mandatory for primary membranous nephropathy with persistent nephrotic ...
We present a 59-year-old patient with type 2 diabetes mellitus and massive nephrotic syndrome (anasa...
The ideal treatment of patients with primary membranous nephropathy (MN) and persistent nephrotic sy...
Kimura disease (KD) is a chronic, inflammatory disorder with slowly developing subcutaneous tumor-li...
The development of well-tolerated and effective therapies that target the pathogenesis of membranous...
IntroductionThere is broad consensus that high-grade basal proteinuria and failure to achieve remiss...
Background/Aims: First-line immunosuppression with the B-cell depleting antibody rituximab reduced p...
Rituximab effectively reduces proteinuria in patients with idiopathic membranous nephropathy (IMN), ...
INTRODUCTION: Patients with phospholipase A2 receptor (PLA2R)-associated membranous nephropathy and ...